Ward Paine, MD
Internal Medicine · Morgantown, WVNPI 1518918614
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,958 of the $5,603 with a category attached, or 88.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,573 and has fallen 64.4% since, to $560 in 2025. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$856
- AstraZeneca$594
- Abbott$526
- Novo Nordisk$420
- Lilly USA, LLC$389
- Amgen$372
- plus $2K from 32 others
Across 219 payments — averaging $23,494 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.1M
- Modernatx, Inc.$599K
- AstraZeneca$547K
- Genentech, Inc.$495K
- Braintree Laboratories, Inc.$122K
- Swedish Orphan Biovitrum AB$65K
- plus $208K from 8 others
What the payments were for
- Travel & lodging$61911%
- Food & beverage$4,95888%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 18 | $856 |
| AstraZeneca | 22 | $594 |
| Abbott | 26 | $526 |
| Novo Nordisk | 29 | $420 |
| Lilly USA, LLC | 25 | $389 |
| Amgen | 23 | $372 |
| Novartis | 24 | $328 |
| Boehringer Ingelheim | 18 | $294 |
| AbbVie(2 entities) | 15 | $264 |
| Sunovion Pharmaceuticals Inc. | 18 | $192 |
| Sanofi-aventis U.S. LLC | 12 | $171 |
| Rhythm Pharmaceuticals, Inc. | 1 | $123 |
| Johnson & Johnson | 5 | $89 |
| Pfizer | 5 | $76 |
| Dexcom, Inc. | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $62 |
| Merck | 4 | $57 |
| Exact Sciences | 3 | $55 |
| Amarin Pharma, Inc. | 4 | $53 |
| Bayer | 3 | $52 |
| GSK | 3 | $45 |
| Organogenesis Inc. | 2 | $41 |
| Melinta Therapeutics, LLC | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $26 |
| Lundbeck LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Medtronic | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,603 in reported general payments places this provider in the 90th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 685 | $275,282 |
| OzempicSemaglutide | 102 | $134,728 |
| JardianceEmpagliflozin | 199 | $130,685 |
| TrulicityDulaglutide | 110 | $106,882 |
| XareltoRivaroxaban | 145 | $79,253 |
| AustedoDeutetrabenazine | 20 | $72,240 |
| MounjaroTirzepatide | 56 | $53,752 |
| JanuviaSitagliptin Phosphate | 47 | $50,145 |
| FarxigaDapagliflozin Propanediol | 143 | $49,506 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $45,404 |
| Repatha SureclickEvolocumab | 39 | $35,084 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $28,529 |
| CreonLipase/Protease/Amylase | 27 | $24,529 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 60 | $24,288 |
| GlatopaGlatiramer Acetate | 31 | $20,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $76 | $289,756731 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $389 | $160,634166 claims |
| Novo NordiskOzempic | $420 | $134,728102 claims |
| Boehringer IngelheimJardiance | $294 | $130,685199 claims |
| Johnson & JohnsonXarelto, Procrit | $89 | $88,327158 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $45 | $79,160127 claims |
| AbbVieCreon, Linzess, Vraylar, Namzaric | $264 | $72,330116 claims |
| MerckJanuvia, Janumet Xr | $57 | $64,27465 claims |
| AstraZenecaFarxiga | $594 | $49,506143 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $19,69782 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $71 | $15,42222 claims |
| NovartisEntresto | $328 | $11,01515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Morgantown
- Shashank PonugotiMorgantown$8K
- Ameenjamal AhmedMorgantown$5K
- Gabriella HorvathMorgantown$4K
- William ChapmanCharleston$1.7M
- David PickeringParkersburg$599K
- Govind PatelFairmont$59K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
- Ali KhanBuckhannon$21K
- Joseph HashemBerkeley Springs$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.